scispace - formally typeset
P

Peter Kurtzhals

Researcher at Novo Nordisk

Publications -  29
Citations -  2569

Peter Kurtzhals is an academic researcher from Novo Nordisk. The author has contributed to research in topics: Insulin & Insulin receptor. The author has an hindex of 16, co-authored 27 publications receiving 2430 citations.

Papers
More filters
Journal ArticleDOI

Correlations of receptor binding and metabolic and mitogenic potencies of insulin analogs designed for clinical use.

TL;DR: The combination of the B31B32diArg and A21Gly substitutions provided insulin glargine with a 6- to 8-fold increased IGF-I receptor affinity and mitogenic potency compared with human insulin, and the reduced in vitro potency of insulin detemir might explain why this analog is not as effective on a molar basis as human insulin in humans.
Journal ArticleDOI

The mechanism of protraction of insulin detemir, a long-acting, acylated analog of human insulin.

TL;DR: Intravenous kinetic studies showed that the clearance and volume of distribution decreased with increasing albumin binding affinity of different acylated insulin analogs, enabling increased predictability of basal insulin.
Journal ArticleDOI

Albumin binding of insulins acylated with fatty acids: characterization of the ligand-protein interaction and correlation between binding affinity and timing of the insulin effect in vivo

TL;DR: It is concluded that the biochemical concept of albumin binding can be applied to protract the effect of insulin, and suggested that derivatization with albumin-binding ligands could be generally applicable to prolong the action profile of peptide drugs.
Journal ArticleDOI

Soluble, fatty acid acylated insulins bind to albumin and show protracted action in pigs.

TL;DR: LysB29-tetradecanoyl des-(B30) insulin might be suitable for providing basal insulin in the treatment of diabetes mellitus, because it does not elicit invasion of macrophages at the site of injection.
Journal ArticleDOI

Synthesis and in vitro characterization of 1-(4-aminofurazan-3-yl)-5-dialkylaminomethyl-1H-[1,2,3]triazole-4-carboxylic acid derivatives. A new class of selective GSK-3 inhibitors.

TL;DR: A novel class of GSK-3 inhibitors with favorable water solubility was identified in a HTS screen and a 3-fold stimulation of the glycogen synthesis in rat soleus muscle was obtained, comparable to the maximal stimulation by insulin itself.